Latest & greatest articles for rheumatoid arthritis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on rheumatoid arthritis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on rheumatoid arthritis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for rheumatoid arthritis

141. Practical Management of Respiratory Comorbidities in Patients with Rheumatoid Arthritis

Practical Management of Respiratory Comorbidities in Patients with Rheumatoid Arthritis 28808949 2018 11 13 2198-6576 4 2 2017 Dec Rheumatology and therapy Rheumatol Ther Practical Management of Respiratory Comorbidities in Patients with Rheumatoid Arthritis. 309-332 10.1007/s40744-017-0071-5 Lung disease is one of the most common causes of extra-articular morbidity and mortality in patients with rheumatoid arthritis (RA). Development of pulmonary manifestations may be due to the systemic (...) , Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK. Deborah.symmons@manchester.ac.uk. eng G1000417 Medical Research Council United Kingdom Journal Article Review 2017 08 14 England Rheumatol Ther 101674543 2198-6576 Disease-modifying antirheumatic drugs Respiratory tract diseases Rheumatoid arthritis Safety Smoking 2017 06 05 2017 8 16 6 0 2017 8 16 6 1 2017 8 16 6 0 ppublish 28808949 10.1007/s40744-017-0071-5 10.1007/s40744-017-0071-5 PMC5696283 J Rheumatol. 2008 Sep;35

Rheumatology and therapy2017 Full Text: Link to full Text with Trip Pro

142. Baricitinib for moderate to severe rheumatoid arthritis

Baricitinib for moderate to severe rheumatoid arthritis Baricitinib for moder Baricitinib for moderate to se ate to sev vere ere rheumatoid arthritis rheumatoid arthritis T echnology appraisal guidance Published: 9 August 2017 nice.org.uk/guidance/ta466 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent the view of NICE, arrived (...) . Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Baricitinib for moderate to severe rheumatoid arthritis (TA466) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 23Contents Contents 1 Recommendations 4 2 The technology 6 3 Committee discussion 7

National Institute for Health and Clinical Excellence - Technology Appraisals2017

143. Acute coronary syndrome in new-onset rheumatoid arthritis: a population-based nationwide cohort study of time trends in risks and excess risks

Acute coronary syndrome in new-onset rheumatoid arthritis: a population-based nationwide cohort study of time trends in risks and excess risks 28710095 2017 07 15 2017 07 15 1468-2060 2017 Jul 14 Annals of the rheumatic diseases Ann. Rheum. Dis. Acute coronary syndrome in new-onset rheumatoid arthritis: a population-based nationwide cohort study of time trends in risks and excess risks. annrheumdis-2016-211066 10.1136/annrheumdis-2016-211066 Acute coronary syndrome (ACS) and other (...) cardiovascular diseases are the main drivers of the increased morbidity and preterm mortality in rheumatoid arthritis (RA). ACS in RA has been linked to inflammation and RA severity. During recent years and with new therapeutic options and treat-to-target strategies, increasing efforts have been made to reach RA remission as soon as possible after diagnosis, and the average level of RA disease activity has declined. Whether this has resulted in declining excess risks for RA comorbidities remains unclear. We

EvidenceUpdates2017

144. The journey of rheumatoid arthritis patients: a review of reported lag times from the onset of symptoms

The journey of rheumatoid arthritis patients: a review of reported lag times from the onset of symptoms 28814904 2018 11 13 1179-156X 9 2017 Open access rheumatology : research and reviews Open Access Rheumatol The journey of rheumatoid arthritis patients: a review of reported lag times from the onset of symptoms. 139-150 10.2147/OARRR.S138830 Even after achieving tremendous advances in diagnosis and treatment of rheumatoid arthritis (RA), many of the patients undergo delays in diagnosis (...) . Department of Medicine, Dr Soleiman Fakeeh Hospital, Jeddah, Saudi Arabia. eng Journal Article Review 2017 07 28 New Zealand Open Access Rheumatol 101688698 1179-156X arthritis delay diagnosis disease management lag time rheumatoid rheumatologists Disclosure The authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or nonfinancial interest in the subject matter or materials discussed in this manuscript. The authors report no conflicts

Open access rheumatology : research and reviews2017 Full Text: Link to full Text with Trip Pro

145. Practical Management of Cardiovascular Comorbidities in Rheumatoid Arthritis

Practical Management of Cardiovascular Comorbidities in Rheumatoid Arthritis 28752316 2018 11 13 2198-6576 4 2 2017 Dec Rheumatology and therapy Rheumatol Ther Practical Management of Cardiovascular Comorbidities in Rheumatoid Arthritis. 293-308 10.1007/s40744-017-0068-0 Cardiovascular (CV) comorbidities are a frequent extra-articular manifestation of rheumatoid arthritis (RA). Cardiovascular disease (CVD) with accelerated atherosclerosis is a major cause of morbidity and mortality in patients (...) , University of Milan, Milan, Italy. Ingegnoli Francesca F Division of Rheumatology, ASST Pini, Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy. eng Journal Article Review 2017 07 27 England Rheumatol Ther 101674543 2198-6576 Accelerated atherosclerosis Biological drugs Cardiovascular comorbidities Cardiovascular disease Disease-modifying anti-rheumatic drugs Inflammation Rheumatoid arthritis 2017 04 24 2017 7 29 6 0 2017 7 29 6 1 2017 7 29 6 0 ppublish 28752316

Rheumatology and therapy2017 Full Text: Link to full Text with Trip Pro

146. Repository corticotropin injection as adjunctive therapy in patients with rheumatoid arthritis who have failed previous therapies with at least three different modes of action

Repository corticotropin injection as adjunctive therapy in patients with rheumatoid arthritis who have failed previous therapies with at least three different modes of action 28790870 2018 11 13 1179-156X 9 2017 Open access rheumatology : research and reviews Open Access Rheumatol Repository corticotropin injection as adjunctive therapy in patients with rheumatoid arthritis who have failed previous therapies with at least three different modes of action. 131-138 10.2147/OARRR.S131046 Many (...) types of treatment are available for patients with rheumatoid arthritis (RA), however, some patients fail to achieve remission. This report aims to determine the safety and efficacy of using repository corticotropin injection (RCI) as an adjunctive therapy in patients with RA refractory to at least three therapeutics with different mechanisms of action. In this open-label, interventional, single-group study, patients received 80 U RCI twice weekly via subcutaneous injection over 12 weeks. Changes

Open access rheumatology : research and reviews2017 Full Text: Link to full Text with Trip Pro

147. The Effect Size of Fibromyalgia on PG-VAS in Rheumatoid Arthritis Patients. Adjustment Proposal in DAS28-ESR: Letter to the Editor regarding Challa, D.N.V., Crowson, C.S. & Davis, J.M. Rheumatol Ther (2017) 4: 201. doi:10.1007/s40744-017-0063-5

The Effect Size of Fibromyalgia on PG-VAS in Rheumatoid Arthritis Patients. Adjustment Proposal in DAS28-ESR: Letter to the Editor regarding Challa, D.N.V., Crowson, C.S. & Davis, J.M. Rheumatol Ther (2017) 4: 201. doi:10.1007/s40744-017-0063-5 28685293 2018 11 13 2198-6576 4 2 2017 Dec Rheumatology and therapy Rheumatol Ther The Effect Size of Fibromyalgia on PG-VAS in Rheumatoid Arthritis Patients. Adjustment Proposal in DAS28-ESR: Letter to the Editor regarding Challa, D.N.V., Crowson, C.S (...) Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Avenida Gonzalitos 235 Norte, Monterrey, Nuevo León, México. Esquivel-Valerio Jorge Antonio JA Servicio de Reumatología, Departamento de Medicina Interna, Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Avenida Gonzalitos 235 Norte, Monterrey, Nuevo León, México. eng Letter 2017 07 06 England Rheumatol Ther 101674543 2198-6576 Fibromyalgia Rheumatoid arthritis 2017 05 28 2017 7 8 6 0

Rheumatology and therapy2017 Full Text: Link to full Text with Trip Pro

148. Tropical pyomyositis caused by Klebsiella pneumoniae with rheumatoid arthritis

Tropical pyomyositis caused by Klebsiella pneumoniae with rheumatoid arthritis 29657883 2018 11 30 2147-9720 5 1 2018 Mar European journal of rheumatology Eur J Rheumatol Tropical pyomyositis caused by Klebsiella pneumoniae with rheumatoid arthritis. 83-84 10.5152/eurjrheum.2017.160126 Carneiro Juliana Brandão Pinto JBP http://orcid.org/0000-0001-7184-0582 Department of Rheumatology, Getúlio Vargas University Hospital (HUGV), Federal University of Amazon School of Medicine (UFAM), Manaus

European journal of rheumatology2017 Full Text: Link to full Text with Trip Pro

149. A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality

A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality 28611082 2017 06 14 2017 06 14 1468-2060 2017 Jun 13 Annals of the rheumatic diseases Ann. Rheum. Dis. A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality. annrheumdis-2017-211138 10.1136/annrheumdis-2017-211138 To compare mortality risks in patients with rheumatoid arthritis-associated interstitial lung (...) , Denmark. Clinic for Rational and Innovative Patient Pathways, Diagnostic Centre, Silkeborg Regional Hospital, Silkeborg, Denmark. eng Journal Article 2017 06 13 England Ann Rheum Dis 0372355 0003-4967 Epidemiology Pulmonary Fibrosis Rheumatoid Arthritis Competing interests: None declared. 2017 01 12 2017 04 04 2017 05 05 2017 6 15 6 0 2017 6 15 6 0 2017 6 15 6 0 aheadofprint 28611082 annrheumdis-2017-211138 10.1136/annrheumdis-2017-211138

EvidenceUpdates2017

150. [Biological agents and tofacitinib in rheumatoid arthritis]

[Biological agents and tofacitinib in rheumatoid arthritis] [Biological agents and tofacitinib in rheumatoid arthritis] [Biological agents and tofacitinib in rheumatoid arthritis] Gonzalez L, López A, Secco A, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation (...) Gonzalez L, López A, Secco A, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A. [Biological agents and tofacitinib in rheumatoid arthritis] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Documentos de Evaluación de Tecnologías Sanitarias, Informe de Respuesta Rapida No 521. 2017 Authors' conclusions High-quality evidence shows that adalimumab, etanercept, infliximab, certolizumab, golimumab, abatacept, tocilizumab, rituximab and tofacitinib

Health Technology Assessment (HTA) Database.2017

151. Sarilumab (Kevzara) - for treating adults with moderate to severe rheumatoid arthritis

Sarilumab (Kevzara) - for treating adults with moderate to severe rheumatoid arthritis 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2017. Reproduction is authorised provided the source is acknowledged. 21 April 2017 EMA/292840/2017 Committee for Medicinal Products for Human Use (CHMP) Assessment (...) Enhanced Pre- and Postnatal Development Fc Fragment crystallizable gp130 glycoprotein 130 IL-6Ra Interleukin-6 receptor alpha IV Intravenous KLH Keyhole limpet hemocyanin NCA non-compartmental analysis NOAEL No observed adverse effect level RA rheumatoid arthritis SC Subcutaneous sIL-6Ra soluble IL-6Ra STAT3 Signal transducer and activator of transcription 3 TK toxicokinetics Clinical ACR American College of Rheumatology ACR20 American College of Rheumatology 20% improvement ACR50 American College

European Medicines Agency - EPARs2017

152. Evaluation of the diagnostic accuracy of hand and foot MRI for early Rheumatoid Arthritis

Evaluation of the diagnostic accuracy of hand and foot MRI for early Rheumatoid Arthritis 28460018 2017 05 01 2017 05 01 1462-0332 2017 Apr 27 Rheumatology (Oxford, England) Rheumatology (Oxford) Evaluation of the diagnostic accuracy of hand and foot MRI for early Rheumatoid Arthritis. 10.1093/rheumatology/kex167 To assess the diagnostic value of MRI for early RA. In some RA patients, a classifiable diagnosis cannot be made at first presentation; these patients present with unclassified (...) Saskia S Department of Clinical Epidemiology. Department of Medical Statistics, Leiden University Medical Center, Leiden, The Netherlands. Reijnierse Monique M Department of Radiology. van der Helm-van Mil Annette H M AHM Department of Rheumatology. eng Journal Article 2017 04 27 England Rheumatology (Oxford) 100883501 1462-0324 early rheumatoid arthritis magnetic resonance imaging rheumatoid arthritis 2016 08 28 2017 5 2 6 0 2017 5 2 6 0 2017 5 2 6 0 aheadofprint 28460018 3782590 10.1093

EvidenceUpdates2017

153. The efficacy of motivational counselling and SMS reminders on daily sitting time in patients with rheumatoid arthritis: a randomised controlled trial

The efficacy of motivational counselling and SMS reminders on daily sitting time in patients with rheumatoid arthritis: a randomised controlled trial 28584189 2017 06 06 2017 06 06 1468-2060 2017 Jun 05 Annals of the rheumatic diseases Ann. Rheum. Dis. The efficacy of motivational counselling and SMS reminders on daily sitting time in patients with rheumatoid arthritis: a randomised controlled trial. annrheumdis-2016-210953 10.1136/annrheumdis-2016-210953 The aim of this report (...) is to investigate the efficacy of an individually tailored, theory-based behavioural intervention for reducing daily sitting time, pain and fatigue, as well as improving health-related quality of life, general self-efficacy, physical function and cardiometabolic biomarkers in patients with rheumatoid arthritis (RA). In this randomised controlled trial 150 patients with RA were randomised to an intervention or a no-intervention control group. The intervention group received three individual motivational

EvidenceUpdates2017 Full Text: Link to full Text with Trip Pro

154. Long-term outcomes after disease activity-guided dose reduction of TNF inhibition in rheumatoid arthritis: 3-year data of the DRESS study - a randomised controlled pragmatic non-inferiority strategy trial

Long-term outcomes after disease activity-guided dose reduction of TNF inhibition in rheumatoid arthritis: 3-year data of the DRESS study - a randomised controlled pragmatic non-inferiority strategy trial 28606961 2017 06 13 2017 06 13 1468-2060 2017 Jun 12 Annals of the rheumatic diseases Ann. Rheum. Dis. Long-term outcomes after disease activity-guided dose reduction of TNF inhibition in rheumatoid arthritis: 3-year data of the DRESS study - a randomised controlled pragmatic non-inferiority (...) strategy trial. annrheumdis-2017-211169 10.1136/annrheumdis-2017-211169 Tumour necrosis factor inhibitors (TNFi) are effective in rheumatoid arthritis (RA), but disadvantages include adverse events (AEs) and high costs. This can be improved by disease activity-guided dose reduction (DR). We aimed to assess long-term outcomes of TNFi DR in RA by using 3-year data from the DRESS study (Dose REduction Strategy of Subcutaneous TNF inhibitors study). In the intervention phase (month 0-18) of the DRESS study

EvidenceUpdates2017

155. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study

Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study 28584187 2017 06 06 2017 07 14 1468-2060 2017 Jun 05 Annals of the rheumatic diseases Ann. Rheum. Dis. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study. annrheumdis-2016-210459 (...) 10.1136/annrheumdis-2016-210459 ABP 501 is a Food and Drug Administration-approved biosimilar to adalimumab; structural, functional and pharmacokinetic evaluations have shown that the two are highly similar. We report results from a phase III study comparing efficacy, safety and immunogenicity between ABP 501 and adalimumab. In this randomised, double-blind, active comparator-controlled, 26-week equivalence study, patients with moderate to severe active rheumatoid arthritis (RA) despite methotrexate

EvidenceUpdates2017 Full Text: Link to full Text with Trip Pro

156. Sarilumab (Kevzara) - To treat adult rheumatoid arthritis

Sarilumab (Kevzara) - To treat adult rheumatoid arthritis Kevzara (sarilumab) Injection U.S. Department of Health and Human Services Search FDA Submit search Kevzara (sarilumab) Injection Kevzara Company: Sanofi Inc. Application No.: 761037 Approval Date: 05/22/2017 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created: July 3

FDA - Drug Approval Package2017

157. Etanercept (Erelzi) - rheumatoid arthritis, juvenile idiopathic arthritis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis

Etanercept (Erelzi) - rheumatoid arthritis, juvenile idiopathic arthritis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2017. Reproduction is authorised provided the source is acknowledged. 21 April 2017 EMA (...) Kilogram MAA Marketing Authorisation Application mg Milligram MMRM Mixed Model Repeated Measure N Na ns Number of Patients Not analysed Not specified PASI Psoriasis Area and Severity Index PC Placebo-controlled PD Pharmacodynamics PK Pharmacokinetics PPS Per-protocol set RA Rheumatoid arthritis SAE Serious Adverse Event SAP Statistical Analysis Plan SD SDV Standard deviation Source Data Verification SmPC Summary of Product Characteristics sTNF soluble Tumour Necrosis Factor TEAE Treatment-emergent

European Medicines Agency - EPARs2017

158. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.

Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. BACKGROUND: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. The Oral Rheumatoid Arthritis triaL (ORAL) Strategy aimed to assess the comparative efficacy of tofacitinib monotherapy, tofacitinib plus methotrexate (...) , and adalimumab plus methotrexate for the treatment of rheumatoid arthritis in patients with a previous inadequate response to methotrexate. METHODS: ORAL Strategy was a 1 year, double-blind, phase 3b/4, head-to-head, non-inferiority, randomised controlled trial in patients aged 18 years or older with active rheumatoid arthritis despite methotrexate therapy. Patients were randomly assigned (1:1:1) to receive oral tofacitinib (5 mg twice daily) monotherapy, oral tofacitinib (5 mg twice daily) plus methotrexate

Lancet2017

159. Clinical and serological characteristics of Ecuadorian patients with rheumatoid arthritis

Clinical and serological characteristics of Ecuadorian patients with rheumatoid arthritis 28652830 2018 11 13 1179-156X 9 2017 Open access rheumatology : research and reviews Open Access Rheumatol Clinical and serological characteristics of Ecuadorian patients with rheumatoid arthritis. 117-122 10.2147/OARRR.S130217 Rheumatoid arthritis (RA) is a systemic autoimmune inflammatory disease, wherein late diagnosis and treatment leads to deformities and disability. The aim of the study was to assess (...) of Rheumatology, Clinical Research Department, Guayaquil, Ecuador. Calapaqui Wendy W Ecuadorian Society of Rheumatology, Clinical Research Department, Guayaquil, Ecuador. Vallejo Carlos C Pontificia Catholic University of Ecuador, Rheumatology Department, Quito, Ecuador. eng Journal Article 2017 06 13 New Zealand Open Access Rheumatol 101688698 1179-156X Ecuador epidemiology rheumatoid arthritis Disclosure The authors report no conflicts of interest in this work. 2017 6 28 6 0 2017 6 28 6 0 2017 6 28 6 1

Open access rheumatology : research and reviews2017 Full Text: Link to full Text with Trip Pro

160. Pathogenetic insights from the treatment of rheumatoid arthritis.

Pathogenetic insights from the treatment of rheumatoid arthritis. Rheumatoid arthritis is a chronic autoimmune disease that causes progressive articular damage, functional loss, and comorbidity. The development of effective biologics and small-molecule kinase inhibitors in the past two decades has substantially improved clinical outcomes. Just as understanding of pathogenesis has led in large part to the development of drugs, so have mode-of-action studies of these specific immune-targeted (...) that subserve diseases like rheumatoid arthritis. Copyright © 2017 Elsevier Ltd. All rights reserved.

Lancet2017